2. Immunology/Inflammation Protein Tyrosine Kinase/RTK
  3. Complement System Syk
  4. GT103

GT103 is a human-derived monoclonal antibody targeting complement factor H (CFH). GT103 binds to a conformationally distinct epitope of CFH on tumor cells. GT103 activates the classical complement pathway, induces complement-dependent cytotoxicity, and triggers antibody-dependent cellular phagocytosis (ADCP) of tumor cells. GT103 increases calreticulin translocation to tumor cell plasma membranes. GT103 mediates B-cell activation via Syk kinase phosphorylation. GT103 inhibits tumor growth and metastasis in animal models. GT103 can be used for the research of non-small cell lung cancer.

For research use only. We do not sell to patients.

GT103

GT103 Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

GT103 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

GT103 is a human-derived monoclonal antibody targeting complement factor H (CFH). GT103 binds to a conformationally distinct epitope of CFH on tumor cells. GT103 activates the classical complement pathway, induces complement-dependent cytotoxicity, and triggers antibody-dependent cellular phagocytosis (ADCP) of tumor cells. GT103 increases calreticulin translocation to tumor cell plasma membranes. GT103 mediates B-cell activation via Syk kinase phosphorylation. GT103 inhibits tumor growth and metastasis in animal models. GT103 can be used for the research of non-small cell lung cancer[1].

Isotype

Human IgG3 kappa
Recommend Isotype Controls
Species Reactivity

Human
In Vitro

GT103 (50 μg/mL; overnight) binds to formalin-fixed, paraffin-embedded human NSCLC tumor tissue sections, with no detectable binding to formalin-fixed, paraffin-embedded normal human lung tissue sections[1].
GT103 (200 μg/mL; 2 h) increases plasma membrane calreticulin expression by approximately 2-fold in NCI-H460 and A549 human lung cancer cells, with no change in total cellular calreticulin levels[1].
GT103 (200 μg/mL; 24 h) significantly increases C3b/iC3b deposition on NCI-H460 and A549 human lung cancer cells via the classical complement pathway, as deposition is reduced in C1q-depleted but not Factor B-depleted serum[1].
GT103 (200 μg/mL; 2 h) significantly increases C1q surface binding to NCI-H460 human lung cancer cells, which is dependent on the antibody's Fc region[1].
GT103 (250 μg/mL; 4 h) significantly enhances macrophage-mediated ADCP of NCI-H460 human lung cancer cells in vitro[1].
GT103 (200 μg/mL; 1-h pre-treatment) significantly increases Syk kinase phosphorylation in human B cells in vitro, in a complement-dependent manner[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

GT103 Related Antibodies

Western Blot Analysis[1]

Cell Line: Human NCI-H460 large cell lung cancer cells; human A549 lung adenocarcinoma cells
Concentration: 200 μg/mL (in the presence of 10% NHS)
Incubation Time: 2 h
Result: Increased normalized calreticulin intensity to 1.92 relative to no antibody control in H460 cells.
Increased normalized calreticulin intensity to 2.23 relative to no antibody control in A549 cells.
Caused an approximate 2-fold increase in plasma membrane calreticulin compared to IgG control for both cell lines.
Showed no change in total calreticulin expression in whole-cell lysates.
In Vivo

GT103 (murine) (200 μg/mouse; i.p.; three times weekly; 2 weeks) inhibits CMT167 growth in C57BL/6 mice, increases tumor calreticulin and complement fragment levels, and upregulates B-cell activation-related genes in tumors[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 (female, 6-8 weeks old, subcutaneous implantation of 2.0 × 105 CMT167 lung tumor cells)[1]
Dosage: 200 μg/mouse
Administration: i.p.; three times weekly; 2 weeks
Result: Reduced tumor growth compared to control treatment.
Induced higher calreticulin mean fluorescence intensity (MFI) in CMT167 tumors.
Increased deposition of C3b/iC3b/C3c fragments in CMT167 tumors.
Increased mean levels of C3dg and C3d in CMT167 tumor lysates, approximately 2-fold higher than control tumors.
Upregulated genes related to B-cell MHC class II antigen presentation, antibody production, germinal center function, and mature B-cell survival in intratumoral B cells.
Clinical Trial
Gene ID

3075  [NCBI]

Accession

P08603
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
SMILES

[GT103]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

GT103 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

GT103GT 103GT-103Complement SystemSykSpleen tyrosine kinasenon-small cell lung cancercomplement-dependent cytotoxicityclassical complement pathwayNCI-H460A549antibody-dependent cellular phagocytosiscomplement factor HSyk kinasetumor cellscalreticulinInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
GT103
Cat. No.:
HY-P991954
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.